Document |
Document Title |
WO/2024/051843A1 |
A pharmaceutical composition for preventing and treating convalescent stage facial nerve paralysis and a use thereof. The pharmaceutical composition contains any one among or a combination of mannitol, sodium aescinate, acyclovir, valacy...
|
WO/2024/054919A1 |
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds can be useful in the treatment of conditions such as depression and related disorders. Orally available formulations and other ph...
|
WO/2024/052895A1 |
This invention provides in some aspects, combinations, compositions and kits comprising a psychedelic drug and an NMD A receptor agonist and applications and uses of same for treating, reducing the incidence of, reducing the severity of ...
|
WO/2024/052553A1 |
A combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin, and a medical product or pharmaceutical composition comprising such combination, useful for the treatment of a variety of diseases and conditio...
|
WO/2024/051631A1 |
Disclosed are a macrocyclic imidazo[1,2-b]pyridazine compound represented by formula (I) or an isotopically labeled compound thereof, or an optical isomer thereof, a geometric isomer, a tautomer thereof or an isomer mixture thereof, or a...
|
WO/2024/051847A1 |
The present invention relates to a pharmaceutical composition for preventing and treating facial nerve micro-entrapment syndrome and a use thereof in the treatment of facial nerve micro-entrapment syndrome. The use comprises joint utiliz...
|
WO/2024/051835A1 |
Use of homovanillic acid and an analog thereof in the preparation of a drug for treating depression. Use of a substance Z in the preparation of a drug. The substance Z is a compound represented by formula I or a pharmaceutically acceptab...
|
WO/2024/051700A1 |
The present invention relates to a novel aryl ether substituted heterocyclic compound having GLP1R agonist activity. Specifically disclosed is a compound having a structure as represented by formula (I) as a GLP1R agonist, or a pharmaceu...
|
WO/2024/051845A1 |
The present invention relates to a pharmaceutical composition for preventing and treating sequelae stage facial nerve paralysis. The pharmaceutical composition is selected from one among or a combination of mouse nerve growth factor, mon...
|
WO/2024/054851A1 |
The present disclosure includes, among other things, macrocyclic CFTR modulators of formula I, pharmaceutical compositions, and methods of making and using the same.
|
WO/2024/052690A1 |
Provided are compounds of the Formula I, and salts, hydrates and solvates thereof: wherein Q, RL and RR are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatm...
|
WO/2024/053721A1 |
[Problem] To provide a therapeutic for spinal cord injury, especially severe spinal cord injury, from the acute phase to the subacute phase, the conventional treatment of which has been difficult. [Solution] A therapeutic for spinal cord...
|
WO/2024/028349A3 |
The present invention relates to levodopa for preventing the development of addiction and/or dependence to prescribed stimulants in a subject treated with stimulants. The present invention also relates to the use of a composition, pharma...
|
WO/2024/054807A1 |
Provided is a pharmaceutical composition including a metal channel activator and a TDP-43 modulator. Also provided is a method of treating a depressive disorder, including administering the pharmaceutical composition. Also provided is a ...
|
WO/2024/054631A1 |
Presented herein are compositions and methods involving mitochondrial organelle transplantation for use in the treatment of traumatic brain injury (TBI), e.g., mild traumatic brain injury (mTBI), in a subject.compositions and methods for...
|
WO/2024/052358A1 |
The present disclosure relates to methods of treating Chronic Inflammatory Demyelinating Polyneuropathy using anti-FcRn antibodies.
|
WO/2024/020188A3 |
Among other things, the present disclosure provides oligonucleotides targeting SARM1 and compositions thereof. In some embodiments, the present disclosure provides methods for preventing or treating various conditions, disorders or disea...
|
WO/2024/050825A1 |
A substituted cyclic compound as represented by formula (I) and having a selective inhibitory effect on MLKL, or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing ...
|
WO/2024/051848A1 |
The present invention relates to an application of a pharmaceutical composition for preparing a drug for preventing and treating nervous system lesions. The pharmaceutical composition for preventing and treating nervous system lesions co...
|
WO/2024/052701A1 |
Provided are compounds of the Formula I, and salts, hydrates and solvates thereof: I wherein Q1, R1, Ra, Rb, Rc, Rd, Re, A1 and A2 are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2α) an...
|
WO/2024/054071A1 |
The present invention relates to a novel compound having histone deacetylase 6 (HDAC6) inhibitory activity, a method for preparing the same, and uses thereof. The novel compound according to the present invention, a stereoisomer thereof ...
|
WO/2024/054791A1 |
The disclosure relates to a combination of active ingredients/adjuvants for the treatment of neurological disorders and diseases such as Alzheimer's disease and mild cognitive impairment (MCI) and memory and cognitive disorders and condi...
|
WO/2024/055015A1 |
The compositions and methods described herein include methods and agents that inhibit inflammasome signaling in a mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle ...
|
WO/2024/052931A1 |
A cell culture protocol for obtaining neural progenitor cells from induced pluripotent stem cells is described. Also described are a pharmaceutical composition and a medicament containing the neural progenitor stem cells for use in the t...
|
WO/2024/020114A3 |
The present disclosure provides compositions and methods for inserting heterologous payload sequences into a target-site in a host cell genome. The compositions and methods use non-LTR retrotransposon reverse transcriptase proteins that ...
|
WO/2024/054996A1 |
Provided herein are methods for treating depression with a fatty acid amide hydrolase (FAAH) cleavable prodrug of a thyroid hormone receptor (TRβ) agonist.
|
WO/2024/054400A1 |
Crystalline 4-((L-valyl)oxy)butanoic acid, methods of preparing crystalline 4-((L- valyl)oxy)butanoic acid, pharmaceutical compositions of crystalline 4-((L-valyl)oxy)butanoic acid, and methods of treatment using crystalline 4-((L-valyl)...
|
WO/2024/054521A1 |
Provided herein are methods and compositions for identifying α-synuclein aggregation inhibitors. Also provided are methods of use of the α -synuclein aggregation inhibitors; the methods include methods of inhibition the formation of Le...
|
WO/2024/054987A1 |
Compositions and methods for diagnosis and treatment of increased risk for mild traumatic brain injury are disclosed.
|
WO/2024/028654A3 |
Provided herein are selective histone deacetylase (HD AC) inhibitors that are useful for treating HD AC6- implicated and/or -mediated diseases, disorders, or conditions. HDAC6 resides in the cytosol and targets non-histone substrates, in...
|
WO/2024/051844A1 |
The present invention relates to a pharmaceutical composition for preventing and treating acute stage facial nerve paralysis, the composition comprising any one among or a combination of an osmotic diuretic drug, an antiviral drug, an an...
|
WO/2024/054416A1 |
The disclosure relates to a combination of active ingredients/adjuvants for the treatment of neurological disorders and diseases such as Alzheimer's disease and mild cognitive impairment (MCI) and memory and cognitive disorders and condi...
|
WO/2024/054875A2 |
Disclosed are methods for mitigating one or more debilitating symptoms of a mTBI for a patient diagnosed with mTBI, e.g. sustained mTBI. These methods comprise administering an effective amount of ghrelin or a variant thereof over multip...
|
WO/2024/050800A1 |
Disclosed in the present invention is a benzopyrazolo-oxazine derivative having a structure as shown in formula I or a pharmaceutically acceptable salt thereof, wherein R is selected from hydrogen, halogen, alkyl and alkoxy, m is an inte...
|
WO/2024/053519A1 |
Disclosed are a kit for diagnosing Alzheimer's disease and a pharmaceutical composition for treating Alzheimer's disease that use EDIL3 or a nucleic acid that encodes EDIL3 as an indicator or a target.
|
WO/2024/051666A1 |
Disclosed are a dibenzylbutyrolactone glycoside compound as shown in formula (I), a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing same, and ...
|
WO/2024/054462A1 |
The embodiments disclose a method of treating stress, anxiety, and anxiety disorders in a human, comprising administering to a human in need of such treatment an effective amount of a pharmaceutical treatment derived from selective Piper...
|
WO/2024/053625A1 |
The purpose of the present invention is to provide a means for shortening the time of development of the action of a local anesthetic agent, an antihistamine drug or the like against skin and oral mucosa. Provided are: a minute project...
|
WO/2024/054412A1 |
Provided herein are methods and compositions for treating at least one symptom of ALS, slowing ALS disease progression, or reducing the deterioration of one or more bodily functions affected by ALS in a subject. The methods can include a...
|
WO/2024/052693A1 |
Provided are compounds of the Formula II, and salts, hydrates and solvates thereof: (Formula (II) wherein R is as defined in the specification. The compounds are prodrugs of inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for ...
|
WO/2024/054415A1 |
The invention relates to the use of scyllo-inositol alone or in combination with other active ingredients including the flavone apigenin to support cognitive health in a subject that takes the product or combination product. The inventio...
|
WO/2024/054811A1 |
Provided is a pharmaceutical composition including a metal channel activator and a glutamate modulator. Also provided is a method of treating a depressive disorder, including administering the pharmaceutical composition. Also provided is...
|
WO/2024/054876A1 |
The present disclosure relates to bifunctional compounds that cause the degradation of LRRK2; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with LRRK2, including Parkinson's Disease.
|
WO/2023/230540A3 |
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain and inflammatory hypersensitivity. The invention also relates to a method for...
|
WO/2024/026481A3 |
The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.
|
WO/2024/052880A1 |
Methods of treating a stress-related disease or disorder such as PTSD, decreasing side effects of 3,4-methylenedioxy-methamphetamine (MDMA), inducing neurite outgrowth, inducing structural neuroplasticity, or increasing brain-derived neu...
|
WO/2024/054452A1 |
Disclosed herein are compositions and methods useful for the treatment or amelioration of various diseases, disorders, or conditions. Some aspects pertain to a pharmaceutical composition comprising 17-ethynyl-10R, 13S-dimethyl 2, 3, 4, 7...
|
WO/2024/050389A1 |
Provided is a pharmaceutical composition including a metal channel activator and an NMDA receptor antagonist. Also provided is a method of treating a depressive disorder, including administering the pharmaceutical composition. Also provi...
|
WO/2024/047078A1 |
The present invention relates to (3S)-1-[5-tert-butyl-3-[(1-methyltetrazol-5- yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol for use in the treatment of diabetic retinopathy, and its methods of treatment thereof.
|
WO/2024/049497A1 |
Disclosed are methods for assessing the presence or absence of a therapeutic concentration of a deuterated docosahexaenoic acid during treatment of a patient with a retinal or neuronal oxidative disease.
|